Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

  title={Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine},
  author={Tam{\'a}s Ferenci and Bal{\'a}zs Sarkadi},
Background: Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries. Methods: Virus neutralizing antibody titres, as a rapidly available but highly predictive surrogate marker, were measured after two doses of the BBIBP-CorV vaccine in 450 subjects. Results were analyzed in a multivariable model accounting for age, sex and time since the administration of… Expand
1 Citations
Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients, and a booster dose is supported for Sinophar recipients, or those with chronic immunosuppressive diseases. Expand


Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines. Expand
Correlates of Protection against symptomatic and asymptomatic SARS-CoV-2 infection
Correlates of protection can be used to bridge to new populations using validated assays and extrapolate efficacy estimates for new vaccines where large efficacy trials cannot be conducted. Expand
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided. Expand
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose. Expand
COVID-19 Vaccination for People with Comorbidities
The efficacy and safety of each COVID-19 vaccine based on the presence and types of comorbidities are presented, and the guidelines recommended by the World Health Organization (WHO), as well as those implemented in the United States of America (USA) and the UK are summarized. Expand
SARS-CoV-2 serology testing: Progress and challenges
The status of COVID-19 serology testing is summarized, challenges are discussed, and future directions for improvement are provided. Expand
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. Expand
Evidence for antibody as a protective correlate for COVID-19 vaccines
Results support the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines. Expand
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
The primary outcomes were safety and tolerability and immunogenicity, assessed as the neutralising antibody responses against infectious SARS-CoV-2, and no serious adverse event was reported within 28 days post vaccination. Expand
Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate
The development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans, and the presence of neutralizing antibodies from prior infection was significantly associated with protection against re-infection. Expand